Company

Umoja BioPharma, Inc.

Umoja BioPharma develops cellular immunotherapies for cancer.

About

Founded in 2019 and based in Seattle, US, Umoja BioPharma develops cellular immunotherapies that retool the immune system to treat tumors. Its pipeline includes TumorTag UB-TT170 and VivoVec UB-VV100. In January 2025, it raised USD 100 million in Series C funding co-led by Double Point Ventures and Data Collective.

4Funding rounds

14Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in